Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced topline results from its Phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran in patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE